Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
1/21/26 Areteia Therapeutics Dexpramipexole for Asthma Subscribers Only Subscribers Only Subscribers Only
1/20/26 Chiesi Farmaceutici Tanimilast for Chronic Obstructive Pulmonary Disease (COPD) Subscribers Only Subscribers Only Subscribers Only
1/19/26 Pulmocide PC-945 for Aspergillosis Subscribers Only Subscribers Only Subscribers Only
1/14/26 Compass Therapeutics (CMPX) tovecimig for Biliary Tract Cancer Subscribers Only Subscribers Only Subscribers Only
1/13/26 Merck & Co., Inc. (MRK) DS-7300 for Small Cell Lung Cancer (SCLC) Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
06/25/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/25/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/26/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
09/08/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
09/17/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update